NCT04442126 - A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

February 6, 2024

Study Completion Date

February 6, 2024

Conditions

Advanced Solid TumorNon-small Cell Lung CancerColorectal CancerSquamous Cell CarcinomaOvarian CarcinomaPeritoneal CarcinomaFallopian Tube CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast Cancer

Interventions

BIOLOGICAL

NM21-1480

Trispecific anti-PD-L1/anti-4-1BB/anti-Human Serum Albumin (HSA) single-chain Fv fusion protein

Trial Locations (26)

10016

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19107

Thomas Jefferson University, Philadelphia

22031

Virginia Cancer Specialists, Fairfax

29425

Medical University of South Carolina (MUSC), Charleston

30912

Augusta University Medical Center, Augusta

37203

Sarah Cannon Cancer Center, Nashville

48197

St. Joseph Mercy Hospital, Ypsilanti

48202

Henry Ford Health System, Detroit

70112

Tulane University Medical Center, New Orleans

77030

The University Of Texas MD Anderson Cancer Center, Houston

80524

UCHealth Poudre Valley Hospital, Fort Collins

03766

Dartmouth Cancer Center, Lebanon

10461-2374

Montefiore Medical Center, The Bronx

Unknown

Hospital Universitario de A Coruna, A Coruña

Hospital Universitario Vall dHebron, Barcelona

Hospital General Universitario de Elche, Elche

Complejo Hospitalario de Jaen, Jaén

Centro Integral Oncologico Clara Campal, Madrid

Clinica Universidad de Navarra - Madrid, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Hospital Universitario Son Llatzer, Palma de Mallorca

Clinica Universidad de Navarra - Pamplona, Pamplona

Hospital Universitario Virgen Macarena, Seville

Hospital Universitari i Politecnic La Fe, Valencia

National Taiwan University Hospital, Taipei